News
EDSA
4.330
+5.10%
0.210
Weekly Report: what happened at EDSA last week (0318-0322)?
Weekly Report · 3d ago
Edesa Biotech Shines at Autoimmune Conference
TipRanks · 6d ago
Weekly Report: what happened at EDSA last week (0311-0315)?
Weekly Report · 03/18 10:55
Weekly Report: what happened at EDSA last week (0304-0308)?
Weekly Report · 03/11 10:52
Edesa Biotech Showcases Innovations at Healthcare Conference
TipRanks · 03/07 21:07
BUZZ-U.S. STOCKS ON THE MOVE-Sea, AeroVironment, Vivid Seats
U.S. Stock index futures dipped on Tuesday. Dow e-minis were down 0.12% at 38,977. The top three NYSE percentage gainers premarket were Sea, AeroVironment and Vivid Seats. Investors await economic data and key events this week.
Reuters · 03/05 12:17
Edesa Biotech Showcases Innovations at Dermatology Events
TipRanks · 03/05 04:07
Weekly Report: what happened at EDSA last week (0226-0301)?
Weekly Report · 03/04 10:55
Weekly Report: what happened at EDSA last week (0219-0223)?
Weekly Report · 02/26 11:05
Weekly Report: what happened at EDSA last week (0212-0216)?
Weekly Report · 02/19 11:07
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Edesa Biotech (EDSA) and Ocular Therapeutix (OCUL)
Analysts have new ratings on Incyte, Edesa Biotech and Ocular Therapeutix. Morgan Stanley has maintained a Hold rating on incyte with a price target of $64.00. The analysts have also reiterated their Buy ratings on the Healthcare sector.
TipRanks · 02/14 11:30
Weekly Report: what happened at EDSA last week (0205-0209)?
Weekly Report · 02/12 10:58
Edesa Biotech Inc reports results for the quarter ended in December - Earnings Summary
Edesa Biotech Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 54 cents per share. The mean expectation of two analysts was for a loss of $1.21 per share; analysts expected zero. Edesa Biotechnology Inc shares had risen by 2.2% this quarter.
Reuters · 02/09 23:18
Edesa Biotech Inc: Current report
Press release · 02/09 23:07
Edesa Biotech GAAP EPS of -$0.54 beats by $0.67
Seeking Alpha · 02/09 21:23
Edesa Biotech Inc <EDSA.OQ> expected to post a loss of $1.21 a share - Earnings Preview
Edesa Biotech Inc expected to post a loss of $1.21 a share - Earnings Preview. The company is expected to show change in quarterly revenue when it reports results on February 8. LSEG's mean analyst estimate for the company is for a loss.
Reuters · 02/06 12:06
Weekly Report: what happened at EDSA last week (0129-0202)?
Weekly Report · 02/05 11:05
Weekly Report: what happened at EDSA last week (0122-0126)?
Weekly Report · 01/29 10:56
BUZZ-U.S. STOCKS ON THE MOVE-B. Riley, Boeing, Archer-Daniels-Midland
U.S. Stock index futures rise on Monday. S&P 500 hit a record high last week. B. Riley Financial, Boeing, Archer-Daniels-Midland are among the day's losers. Macy's and Spirit Airlines rise in premarket trading.
Reuters · 01/22 12:23
Weekly Report: what happened at EDSA last week (0115-0119)?
Weekly Report · 01/22 10:59
More
Webull provides a variety of real-time EDSA stock news. You can receive the latest news about Edesa Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDSA
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.